Tyra Biosciences (NASDAQ:TYRA) Raised to “Hold” at Wall Street Zen

Tyra Biosciences (NASDAQ:TYRA) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

TYRA has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, August 22nd. Raymond James Financial assumed coverage on Tyra Biosciences in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $35.00 target price on the stock. Oppenheimer reissued an “outperform” rating and set a $36.00 price target on shares of Tyra Biosciences in a research report on Wednesday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, October 8th. Finally, Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Tyra Biosciences Stock Down 2.8%

NASDAQ:TYRA opened at $21.50 on Friday. The company has a market capitalization of $1.15 billion, a PE ratio of -11.50 and a beta of 1.09. Tyra Biosciences has a 52-week low of $6.42 and a 52-week high of $22.83. The stock has a fifty day simple moving average of $16.31 and a 200-day simple moving average of $12.73.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting analysts’ consensus estimates of ($0.50). As a group, equities analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current year.

Insider Activity at Tyra Biosciences

In related news, Director Robert J. More sold 246,871 shares of the company’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $20.25, for a total value of $4,999,137.75. Following the completion of the transaction, the director directly owned 3,833,425 shares in the company, valued at approximately $77,626,856.25. This represents a 6.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 15.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Tyra Biosciences

A number of hedge funds have recently added to or reduced their stakes in TYRA. HighVista Strategies LLC increased its stake in shares of Tyra Biosciences by 4.3% during the 2nd quarter. HighVista Strategies LLC now owns 24,962 shares of the company’s stock valued at $239,000 after acquiring an additional 1,021 shares during the last quarter. American Century Companies Inc. grew its holdings in Tyra Biosciences by 5.8% in the first quarter. American Century Companies Inc. now owns 23,431 shares of the company’s stock valued at $218,000 after purchasing an additional 1,289 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after purchasing an additional 1,668 shares during the last quarter. US Bancorp DE increased its position in Tyra Biosciences by 50.5% during the first quarter. US Bancorp DE now owns 5,435 shares of the company’s stock worth $51,000 after purchasing an additional 1,823 shares during the last quarter. Finally, Federated Hermes Inc. raised its stake in Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after purchasing an additional 1,841 shares during the period. 84.14% of the stock is owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.